REVIEW

The Role of Angiotensin II in Poisoning-Induced Shock—a Review

Andrew Chen¹ · Anselm Wong²,³

Received: 19 December 2021 / Revised: 7 February 2022 / Accepted: 9 February 2022 / Published online: 8 March 2022 © The Author(s) 2022

Abstract

Background  Shock in drug poisoning is a life-threatening condition and current management involves fluid resuscitation and vasopressor therapy. Management is limited by the toxicity of high-dose vasopressors such as catecholamines. Clinical trials have shown the efficacy of angiotensin II as an adjunct vasopressor in septic shock. The aim of this review is to assess the use of angiotensin II in patients with shock secondary to drug overdose.

Methods Medline (from 1946), Embase (from 1947) and PubMed (from 1946) databases were searched until July 2021 via OVID. Included studies were those with shock due to drug poisoning and received angiotensin II as part of their treatment regimen. Of the 481 articles identified, 13 studies (case reports and scientific abstracts) were included in the final analysis with a total of 14 patients. Extracted data included demographics, overdose drug and dosage, angiotensin II dosage, time of angiotensin II administration, haemodynamic changes, length of hospital stay, mortality, complications, cardiac function and other treatment agents used.

Results  Thirteen studies were included consisting of 6 case reports, 6 scientific abstracts and 1 case series. Overdose drugs included antihypertensives (n = 8), psychotropics (n = 4), isopropanol (n = 1) and tamsulosin (n = 1). Out of a total of 14 patients, 3 patients died. Ten patients had their haemodynamic changes reported. In terms of MAP or SBP changes, three patients (30%) had an immediate response to angiotensin II, four patients (40%) had responses within 30 min, one patient (10%) within two hours and two patients (20%) did not have their time reported. Two patients were shown to have direct chronotropic effects within 30 min of angiotensin II administration. The median hospital stay for patients was 5 days (IQR = 4). The time from overdose until angiotensin II administration ranged from 5 to 56 h. Other vasopressors used included phenylephrine, noradrenaline, adrenaline, vasopressin, dobutamine, dopamine, methylene blue and ephedrine. A median of 3 vasopressors were used before initiation of angiotensin II. Twelve patients received angiotensin II as their final treatment.

Conclusions  Angiotensin II may be useful as an adjunct vasopressor in treating shock secondary to drug poisoning. However, the current literature consisted of only very low-quality studies. To truly assess the utility of angiotensin II use in drug-induced poisoned patients, further well-designed prospective studies are required.

Keywords  Angiotensin II · Shock · Drug poisoning · Overdose

Introduction

Shock is a life-threatening condition where low blood pressure leads to impaired organ perfusion [1]. Maintaining an adequate mean arterial pressure (MAP) is crucial for organ protection as the duration of hypotension is associated with increased organ injury [2]. If left untreated, it can lead to death from multiple organ failure and impaired oxygen utilisation [3]. Current management of shock involves aggressive fluid resuscitation and vasopressor therapy [4]. Vasopressors such as catecholamines and vasopressin are available for clinicians to use as part of conventional management of peripherally shocked patients.
Currently, there is no evidence that one vasopressor is superior over another in terms of mortality, with the exception of dopamine, which has a higher risk of arrhythmia and 28-day mortality when compared to noradrenaline [1].

Angiotensin II is an endogenous octapeptide that is a major component of the renin–angiotensin–aldosterone system (RAAS) [6]. It regulates blood pressure through a variety of mechanisms including smooth muscle vasoconstriction of peripheral vessels, reabsorption of water via anti-diuretic hormone (ADH) and potentiating the release of aldosterone [7]. Angiotensin-converting enzyme type-1 (ACE-1) is present in the lungs and aids the cleavage of angiotensin I into angiotensin II [8]. To exert its haemodynamic effect, angiotensin II stimulates AT-1 receptors in the peripheral vasculature [9]. Intravenous angiotensin II has a half-life of less than one minute in circulation and 15 to 30 min in tissue [10]. Clearance is independent of hepatic or renal function but the official prescribing information notes that formal studies have not examined its metabolism [11].

In certain circumstances, management of shock in poisoned patients may be refractory to standard treatment. For example, combined overdoses of dihydropyridine calcium channel blockers with angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEIs) can lead to a refractory shock [12]. Given the wide range of indications for antihypertensives such as beta blockers, as well as their relatively narrow therapeutic index, the potential for death following overdose is significant [13]. Therefore, there may be a role for angiotensin II in cases of drug-induced shock.

Two recent randomised controlled trials have shown the effectiveness of angiotensin II in patients with distributive and vasodilatory shock that did not respond to conventional management [14, 15]. The largest randomised controlled trial (ATHOS-3) to date found that a significantly greater number of patients who received angiotensin II reached primary endpoints with respect to MAP at the 3-h mark when compared to placebo [15]. This led to its approval by the US Food and Drug Administration (FDA) in 2017 and European Medicines Agency (EMA) in 2019 for the treatment of hypotension in patients with septic or other distributive shock [16, 17].

Previous reviews have focused on angiotensin II and its use in the context of various forms of shock including cardiogenic, septic, haemorrhagic and neurogenic forms [18–20]. However, there has been little focus on shocked patients secondary to drug poisoning. This review aims to explore the use of angiotensin II as an adjunct vasopressor in the context of circulatory shock secondary to drug-induced toxicity.

Methodology

A systematic review was performed across several databases including Medline (from 1946), Embase (from 1947) and PubMed (from 1946) up until 28th July 2021. The search strategy was developed based on the search strategies of similar systematic reviews investigating shock and drug poisoning [13, 18]. A detailed search strategy is outlined in Tables 2 and 3 in the Appendix.

Search Terms

Medical Subject Headings (MeSH) terms were used in OVID to search Medline and Embase databases. Search terms included ‘exp Renin-angiotensin system’ OR ‘exp angiotensin II’ AND ‘exp shock’ OR ‘exp hypotension’ OR ‘exp vasodilation’ AND ‘exp drug overdose’ OR ‘exp poisoning’. MeSH terms were appropriately translated from MEDLINE to Embase. An additional search of PubMed using the terms angiotensin II and overdose was performed.

Inclusion and Exclusion Criteria

For inclusion in the analysis, study subjects must have received angiotensin II as an adjunct or secondary treatment for shock. All studies including controlled trials, observational studies, case reports and abstracts from scientific meetings without date restrictions were included. References of included studies were also explored for additional articles. Studies were excluded if they did not include patients who had drug-induced toxicity from overdose. Two investigators agreed on the final inclusion of papers from the literature search.

Outcome Measures

The primary outcome was mortality. Secondary outcomes included the change in haemodynamic parameters such as MAP or systolic blood pressure (SBP) in association with angiotensin II, length of stay in hospital and reduction of overall catecholamine requirements.

Quality Assessment

The GRADE (Grading of Recommendations, Assessment, Development and Evaluations) method was used to assess the quality of the studies to assist any future guidelines on poisoning management [21]. GRADE provides a reproducible and transparent framework for grading evidence with specific domains, which increase or decrease the level of confidence in the evidence [22]. Domains which decrease
quality of evidence include risk of bias, imprecision, inconsistency, indirectness and publication bias [23]. There are domains which increase the quality of evidence, but these situations are rare [24].

Results

The initial search was performed without language restrictions or limitation to research design, which yielded 481 articles, of which 42 (9%) were duplicates. The remaining 439 title and abstracts were screened. This resulted in 31 (7%) full-text relevant articles being identified. Out of these studies, 19 studies were excluded as they did not include the correct patient population (shock induced by overdose). Twelve articles remained after review of full texts. An additional study was found via a secondary search through the references of included studies [25, 26]. Of the remaining 13 articles, six were case reports, six were scientific abstracts and one was a case series (defined as two or more cases of drug overdose reported together). The article selection process is detailed in Fig. 1.

Angiotensin II in Overdose Patients

From the literature search, six case reports, six scientific abstracts and one case series revealed 14 patients with refractory shock due to drug overdose who were administered angiotensin II as an adjunct part of their treatment. There were no randomised controlled trials or observational studies describing angiotensin II as a treatment in poisoned patients. Patients were hypotensive due to antihypertensives \((n = 8)\), psychotropics \((n = 4)\), isopropanol \((n = 1)\) and tamsulosin \((n = 1)\). The antihypertensives included amlodipine, carvedilol, lisinopril, spironolactone, hydralazine, furosemide, hydrochlorothiazide, diltiazem, benazepril, enalapril and verapamil. Psychotropics included doxepin, clozapine, diazepam, risperidone, valproic acid, bupropion, venlafaxine and temazepam. Patients were aged from 18 to 65, comprising six females (43%) and eight males (57%).

The main outcome measures that were reported included mortality and changes in MAP/SBP. Out of the 14 patients, three patients (21%) died despite receiving angiotensin II. Ten patients had positive haemodynamic responses reported in terms of MAP or SBP. Eight patients had their response time recorded, all of which occurred within two hours. Two patients were reported to have positive chronotropic effects following angiotensin II administration. Twelve patients received angiotensin II as their final treatment. Nine patients had their initiation of angiotensin II post overdose reported. One patient had the time of initiation reported after receiving first-line vasopressors. The most common disposition was being discharged to psychiatric team. A detailed summary is listed in Table 1.

Risk of Bias

As expected, all studies were classified as ‘very low’ quality using the GRADE criteria due to the nature of the study design (case reports and abstracts). Risk of bias was high due to the considerably high risk of publication, confounding, confirmation and observer bias. A detailed table is listed in Table 4 in the Appendix.
| Study | Age (years) | Sex | Echocardiography results | SVR reported | Drug | Poisoning dose | Ang II dose | Time post overdose Ang II administered | Change following Ang II | Hospital stay | Mortality | Complications post Ang II administration | Pre-angiotensin II treatment |
|-------|-------------|-----|--------------------------|--------------|------|----------------|------------|----------------------------------------|------------------------|--------------|-----------|----------------------------------------|---------------------------|
| 1. Ferdowsali et al. (2020) [27] | 42 | F | NR | 595 dyn/s per cm$^2$ before Ang II | TCA doxepin | 21 tablets of unknown strength | 10 ng/kg/min for ~2 days | NR | Within 5 min, MAP ↑ to 67 mmHg | NR | 9 days | Died | Encephalopathy, Acute respiratory distress syndrome secondary to aspiration pneumonitis | Phenylephrine, noradrenaline (noradrenaline-equivalent) dose: 0.55 μg/kg/min |
| 2. Carpenter et al. (2019) [28] | 24 | F | EF of 40% (from 25%) 15 min after Ang II | NR | Amlodipine, carvedilol, lisinopril, spironolactone, hydralazine, isosorbide mononitrate, furosemide and aspirin | 10 ng/kg/min for ~24 h | 9 h | Within 15 min, MAP ↑ by 12 mmHg and HR ↑ by 7 beats/min | NR | 5 days | Alive | Acute kidney injury on hospital day 2, returning to normal on day 5 | Activated charcoal: 50 g Noradrenaline: 10 μg/min Adrenaline: 0.04 U/min Glucagon IV: 5 mg Hydrocortisone sodium succinate: 100 mg/8 h |
| 3. Guo et al. (2019) [29] | 65 | M | EF of 45–50% with grade 1 diastolic dysfunction and abnormal septal motion 30 min after Ang II | NR | Carvedilol, Lisinopril/ hydrochlorothiazide | 750 mg (12.5 mg×60 tablets) 300 mg (10 mg×30 tablets) 20/25 mg (unknown amount) | 10 ng/kg/min for ~3 days | 5 h | Within 30 min, MAP ↑ to 66 mmHg (from 59) and HR ↑ to 61 beats/min (from 47) | NR | 3 days | Alive | No complications | Glucagon IV: 2 mg Noradrenaline: 40 μg/min Adrenaline: 11 μg/min Hyperinsulinemia-euglycemia: IV bolus of 1 U/kg followed by infusion at 1 U/kg/h |
| 4. Trilli et al. (1994) [30] | 45 | M | NR | NR | Metformin, valproic acid, risperidone and trazodone | 80 ng/kg/min for ~17 h | NR | Vasopressin was ceased upon starting Ang II | NR | 5 days | Alive | NR | High doses of noradrenaline, adrenaline, vasopressin and phenylephrine L-carnitine Continuous renal replacement therapy |

| Study | Age (years) | Sex | Echocardiography results | SVR reported | Drug | Poisoning dose | Ang II dose | Time post overdose Ang II administered | Change following Ang II | Hospital stay | Mortality | Complications post Ang II administration | Pre-angiotensin II treatment |
|-------|-------------|-----|--------------------------|--------------|------|----------------|------------|----------------------------------------|------------------------|--------------|-----------|----------------------------------------|---------------------------|
| 1. Ferdowsali et al. (2020) [27] | 42 | F | NR | 595 dyn/s per cm$^2$ before Ang II | TCA doxepin | 21 tablets of unknown strength | 10 ng/kg/min for ~2 days | NR | Within 5 min, MAP ↑ to 67 mmHg | NR | 9 days | Died | Encephalopathy, Acute respiratory distress syndrome secondary to aspiration pneumonitis | Phenylephrine, noradrenaline (noradrenaline-equivalent) dose: 0.55 μg/kg/min |
| 2. Carpenter et al. (2019) [28] | 24 | F | EF of 40% (from 25%) 15 min after Ang II | NR | Amlodipine, carvedilol, lisinopril, spironolactone, hydralazine, isosorbide mononitrate, furosemide and aspirin | 10 ng/kg/min for ~24 h | 9 h | Within 15 min, MAP ↑ by 12 mmHg and HR ↑ by 7 beats/min | NR | 5 days | Alive | Acute kidney injury on hospital day 2, returning to normal on day 5 | Activated charcoal: 50 g Noradrenaline: 10 μg/min Adrenaline: 0.04 U/min Glucagon IV: 5 mg Hydrocortisone sodium succinate: 100 mg/8 h |
| 3. Guo et al. (2019) [29] | 65 | M | EF of 45–50% with grade 1 diastolic dysfunction and abnormal septal motion 30 min after Ang II | NR | Carvedilol, Lisinopril/ hydrochlorothiazide | 750 mg (12.5 mg×60 tablets) 300 mg (10 mg×30 tablets) 20/25 mg (unknown amount) | 10 ng/kg/min for ~3 days | 5 h | Within 30 min, MAP ↑ to 66 mmHg (from 59) and HR ↑ to 61 beats/min (from 47) | NR | 3 days | Alive | No complications | Glucagon IV: 2 mg Noradrenaline: 40 μg/min Adrenaline: 11 μg/min Hyperinsulinemia-euglycemia: IV bolus of 1 U/kg followed by infusion at 1 U/kg/h |
| 4. Trilli et al. (1994) [30] | 45 | M | NR | NR | Metformin, valproic acid, risperidone and trazodone | 80 ng/kg/min for ~17 h | NR | Vasopressin was ceased upon starting Ang II | NR | 5 days | Alive | NR | High doses of noradrenaline, adrenaline, vasopressin and phenylephrine L-carnitine Continuous renal replacement therapy |
**Table 1 (continued)**

| Study                  | Age (years) | Sex | Echocardiography results | SVR reported Drug | Poisoning dose | Ang II dose | Time post overdose Ang II administered | Change following Ang II | Hospital stay | Mortality | Complications post Ang II administration | Pre-angiotensin II treatment |
|------------------------|-------------|-----|--------------------------|-------------------|----------------|-------------|-----------------------------------------|-------------------------|---------------|-----------|------------------------------------------|-----------------------------|
| 5. Quinn et al. (2021) [31] | 50          | M   | NR                       | Pulmonary artery catheterisation revealed low cardiac indices (<2.3), low central venous oxygen saturations (<70%), high filling pressures and low systemic vascular resistance before Ang II | Dilatazem, bupropion and venlafaxine | NR          | 35 ng/kg/min for 18 h | NR | Immediate MAP sustained above 65 (from 40-50 s) | 3 days | Alive | NR | Noradrenaline: 300 μg/min Vasopressin 0.04 U/min Adrenaline: 20 μg/min Dopamine: 2 μg/min One-to-one diastolic augmentation via intra-aortic balloon pump |
| 6. Gutierrez et al. (2019) [32] | 57          | M   | NR                       | Amlodipine and benazepril | NR          | 20–80 ng/kg/min for 4 days | NR | Within 2 h, adrenaline was weaned off and noradrenaline ↓ by 50% 4 days later, all vasopressors were weaned off | 8 + days | Alive | No persistent end-organ failure | Calcium gluconate: 4 g Glucagon: 10 mg High-dose euglycemic therapy: IV insulin 3.5 units/kg/h 20% lipid emulsion: 1.5 mL/kg bolus x 2 Noradrenaline, phenylephrine and vasopressin |
| 7. Jackson et al. (1993) [26] | 44          | M   | NR                       | Enalapril Verapamil Temazepam | 600 mg (20 mg x 30 tablets) 720 mg (240 mg x 30 tablets) 100 mg (10 mg x 10 tablets) | 3–18 μg/kg/min for 3 h 5 μg/kg/min for final 2 h | 8 h after other vasopressors were given | SBP sustained to above 100 mmHg within 2 h | NR | Alive | NR | Calcium gluconate, ephedrine and atropine Dopamine: 3 μg/kg/min Adrenaline: 0.02 μg/kg/min |
| 8. Eisenstat et al. (2020) [33] | 65          | M   | NR                       | Tamsulosin Genova (elvitegravir, cobicistat, emtricitabine, tenofovir) Darunavir | 12 mg (0.4 mg x 30 tablets) 150–150–200–10 mg (30 tablets) 24,000 mg (800 mg x 30 tablets) | NR | ~ 10 h | NR | Alive | Painless electrical activity arrest | Noradrenaline, phenylephrine, vasopressin |
| 9. Newby et al. (1995) [25] | 46          | F   | Good left ventricular function without pericardial effusion before Ang II | Enalapril Strong lager | 1724 dyns per cm² before Ang II | 140–200 mg (10 mg x 14-20 tablets) 5 pints | 22 ng/kg/min for 30 h | BP ↑ to 110/70 mmHg (from 80/50) | Urine output ↑ to 1500 mL in 4 h (from anuria) | NR | Alive | No complications | Dopamine: 2.5 μg/kg/min Noradrenaline: bolus 1 mg over 2 min |
### Table 1 (continued)

| Study | Age (years) | Sex | Echocardiography results | SVR reported | Drug | Poisoning dose | Ang II dose | Time post overdose Ang II administered | Change following Ang II administration | Hospital stay | Mortality | Complications post Ang II administration | Pre-angiotensin II treatment |
|-------|-------------|-----|--------------------------|--------------|------|----------------|-------------|----------------------------------------|--------------------------------------|--------------|-----------|------------------------------------------|--------------------------|
| 10. Ulici et al. (2021) [34] | 18 | F | EF of 65–70% with HR 130 (unknown whether before/after Ang II) | NR | Amlodipine, Carvedilol, furosemide and hydrochlorothiazide | 300 mg 30 tabs of unknown strength (25 mg hydrochlorothiazide) | 40 ng/kg/min | 20 h | Noradrenaline, high-dose insulin, Ang II, vasopressin, phenylephrine required to maintain MAP above 50 mmHg | Vasopressors weaned off after 5 days | 9 + days Alive | Good neurological outcome | Calcium gluconate: 2 mg Intralipid: 9 units/kg/hour Noradrenaline: 0.45 μg/kg/min Vasopressin: 2.4 units/min Phenylephrine Methylene blue: bolus 1 mg/kg and infusion 2 mg/kg/hour VA-ECMO |
| 11. Wieruszewski et al. (2020) [35] | 39 | M | Hyperdynamic ventricles with grossly preserved EF and no pericardial effusion before Ang II | NR | Clozapine | 11 g | 20 ng/kg/min for 8 h 30 mg/kg/min for final 8 h | –8 h | Within minutes, MAP ↑66 mmHg (from 50–55) | No change in urine output (consistent oliguria) after 6 h | After 8 h, noradrenaline and adrenaline down titrated to 0.5 μg/kg/min and 0.04 U/min respectively | After 16 h, noradrenaline and vasopressin down titrated to 0.1 μg/kg/min and 0.08 U/min respectively | All vasopressors stopped after 18 h | Persistent oliguria and acidosis—leading to renal replacement therapy Recovered renal function at discharge |
| 12. Tovar et al. (1997) [36] | 34 | F | NR | NR | Enalapril Ramipril Amlodipine Nitrendipine | 200 mg 110 mg 110 mg 600 mg | 5–15 μg/mm for 24 h 7.5 h | | Almost immediately, SBP rose from 50 to 100 mmHg | Noradrenaline reduced to 10 μg/min Immediate improvement in diuresis output and disappearance of cardiac failure signs After 72 h, all vasopressors treatment stopped | | 4 + days Alive | Patient totally recovered | IV calcium gluconate: 1000 mg Dopamine: 4.9 μg/kg/min Noradrenaline: 60 μg/min |
| 13. Chieng et al. (2021) [37] | 44 | F | Hyperdynamic left ventricle before Ang II | NR | Isopropanol Diazepam | Up to 500 mL of isopropanol 60% and chlorhexidine 0.5% 5 mg | 20–70 mg/kg/min for 4 h 12.5 h | | After 3.5 h, methylene blue and vasopressin weaned off | | | | 5 + days Alive | Remained well | Noradrenaline: 90 μg/min Vasopressin: 0.04 units/min Methylene blue: 1 mg/kg/hour CVVHDF |

CO, cardiac output; CVVHDF, continuous venovenous haemodiafiltration; echo, echocardiogram; EF, ejection fraction; F, female; HR, heart rate; IV, intravenous; M, male; MAP, mean arterial pressure; NR, not reported; N/A, not applicable; SBP, systolic blood pressure; SVR, systemic vascular resistance; TCA, tricyclic antidepressant; VA-ECMO, venoarterial extracorporeal membrane oxygenation
Discussion

The quality of evidence examining angiotensin II in drug-induced poisoning was very low as per the GRADE methodology. There were often confounding factors due to the institution of multiple treatments involving multiple medications. No studies examined differences in length of hospital stay or compared treatments.

Mortality

Out of the 14 patients across the 13 studies, three patients (21%) died despite restoration of blood pressure after angiotensin II infusion. These included poisoning from lisinopril, tamsulosin and doxepin. Although initially recovering from their period of hypotension, these deaths were due to complications from catheter-related sepsis (with lisinopril) and a combination of encephalopathy and ARDS (with doxepin). Details of the third fatality were lacking.

Historically, septic shock that was refractory to conventional vasopressors had mortality rates as high as 90% [38]. Refractory shock is common and despite advances in therapy, the mortality of patients with shock remains as high as 30–50% [39]. The ATHOS-3 trial did not show any short or long-term mortality benefit in the angiotensin II treatment group when compared to the placebo group [15]. However, it did demonstrate that the angiotensin I/angiotensin II ratio was predictive of both blood pressure and mortality [15]. Eighty percent of patients in this trial had shock due to sepsis, with a median age of 64. This is in contrast to poisoned patients who are usually younger and were less likely to have premorbid comorbidities.

Mean Arterial Pressure, Systolic Blood Pressure, Heart Rate and Treatment Times

Maintaining adequate perfusion is crucial in drug-induced hypotension to allow for the clearance of the toxic metabolites [29, 31]. Other agents that were used included phenylephrine, noradrenaline, adrenaline, vasopressin, dobutamine, dopamine, methylene blue and ephedrine. Ten patients had their haemodynamic changes reported, with eight patients having their response time in relation to MAP or SBP improvement described. In terms of MAP or SBP changes, three patients (30%) had an immediate response to angiotensin II, four patients (40%) had responses within 30 min, one patient (10%) within two hours and two patients (20%) did not have their time reported. Six patients (60%) had their MAP reported and five patients achieved a MAP of > 65 mmHg after angiotensin II treatment, with one patient reaching a MAP of > 50. SBP changes were reported in the remaining four patients (40%), with three patients achieving a SBP of > 100 and one patient achieving a SBP of > 70. Across all 14 patients, 12 patients (86%) had their treatment times reported, which ranged from 4 to 120 h.

Angiotensin II does not typically exhibit chronotropic or inotropic effects [4]. One case series reported direct chronotropic changes, where two patients had an increase in heart rate within 30 min of angiotensin II administration [28]. Busse et al.‘s recent literature review demonstrated the successful use of angiotensin II in patients with shock from various aetiologies including distributive, cardiogenic and haemorrhagic [18]. However, the evidence consisted of mostly low-quality studies such as case reports and was subject to publication bias [18]. Angiotensin II has been approved for use only in cases of vasodilatory shock refractory to standard vasopressor therapy [11]. In our review, angiotensin II was used in a heterogeneous group of drug-induced shock which may have included cardiogenic or vasoplegic shock. Only a few studies mentioned cardiac function investigations.

Other Cardiovascular Support Treatments

Nine patients (64%) had their weaning period of first-line vasopressors reported, which ranged from 2 to 48 h. This finding is consistent with ATHOS and ATHOS-3 trials where all patients receiving angiotensin II had a reduction in catecholamine requirements [14, 15]. Additionally, the vasopressor dose required to maintain MAP is highly predictive of short-term mortality in critically ill patients [40–43]. However, vasopressor reductions that occur across days may be due to a combination of both the elimination of toxic metabolites and the effect of angiotonin II itself. The elimination of drugs is dependent on the half-life of the drug and the amount ingested.

There have been numerous case reports describing the use of venoarterial and venovenous ECMO for the treatment of drug-induced shock from antihypertensives and antidepressants [44–46]. ECMO in the clinical setting should be considered in patients with cardiorespiratory failure who deteriorates rapidly despite maximal conventional treatment [47]. During ECMO therapy, angiotensin II levels are reduced as blood bypasses the lung where angiotensin I is converted into angiotensin II [48]. In this review, one patient exhibited successful treatment with ECMO after receiving angiotensin II [34]. Another patient did not require ECMO after angiotensin II was administered [31].

Limitations

This systematic literature review has various limitations. Primarily, all literatures were of very low evidence as only case reports, case series and scientific abstracts were found. The assessment of mortality was limited due to the small nature
of the same size. As with all case reports, a comparator population was not available, which makes it difficult to establish whether patients would have improved with standard treatment. Finally, this review is limited by reporting bias as reporting was not standardised and improvement in relation to timing was not always stated. Further randomised controlled trials with larger sample sizes are needed to address these limitations.

### Appendix

#### Table 2 Search Strategy: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations and Daily <1946 to July 28, 2021>

|   | Description                                                                 | Count |
|---|-----------------------------------------------------------------------------|-------|
| 1 | exp Renin-Angiotensin System/ or exp Angiotensin II/                        | 52,515|
| 2 | (hypertensin or angiotonin or ‘angiotensin II’ or ‘angiotensin 2’).tw       | 51,646|
| 3 | 1 or 2                                                                      | 74,225|
| 4 | exp Shock, Cardiogenic/ or exp Shock/ or exp Shock, Hemorrhagic/ or exp Shock, Septic/ | 79,131|
| 5 | exp Hypotension/ or exp Vasodilation/                                       | 60,994|
| 6 | vasodilatory shock.mp                                                       | 295   |
| 7 | 4 or 5 or 6                                                                 | 137,854|
| 8 | exp Poisoning/                                                              | 161,837|
| 9 | exp Opiate Overdose/ or exp Drug Overdose/                                  | 12,500|
| 10| exp Chemically-Induced Disorders/                                           | 515,125|
| 11| (overdose* or poisoning or toxicity or intoxication or ingestion* or adverse effect* or medication error*).tw | 732,215|
| 12| 8 or 9 or 10 or 11                                                          | 1,161,793|
| 13| 3 and 7 and 12                                                              | 71    |

#### Table 3 Search Strategy: Embase Classic + Embase <1947 to 2021 Week 29>

|   | Description                                                                 | Count |
|---|-----------------------------------------------------------------------------|-------|
| 1 | exp renin angiotensin aldosterone system/ or exp angiotensin II/            | 71,589|
| 2 | (hypertensin or angiotonin or ‘angiotensin II’ or ‘angiotensin 2’).tw       | 67,857|
| 3 | 1 or 2,108,545                                                              | 108,545|
| 4 | exp shock/ or exp cardiogenic shock/ or exp hemorrhagic shock/ or exp septic shock/ | 157,924|
| 5 | exp hypotension/ or exp vasodilatation/                                     | 250,500|
| 6 | vasodilatory shock.mp                                                       | 476   |
| 7 | 4 or 5 or 6                                                                 | 391,279|
| 8 | exp intoxication/                                                            | 439,832|
| 9 | exp drug overdose/                                                           | 31,108 |
| 10| exp chemically induced disorder/                                            | 121,393|
| 11| (overdose* or poisoning or toxicity or intoxication or ingestion* or adverse effect* or medication error*).tw | 1,031,784|
| 12| 8 or 9 or 10 or 11                                                          | 1,415,370|
| 13| 3 and 7 and 12                                                              | 409   |

### Conclusion

Angiotensin II may be useful as an adjunct vasopressor in treating shock secondary to drug poisoning. However, the current literature consisted of only very low-quality studies. To truly assess the utility of angiotensin II use in drug-induced poisoned patients, further well-designed prospective studies are required.
Table 4 Quality assessment

| Authors                  | GRADE factors | Study design | Risk of bias | Imprecision | Inconsistency | Indirectness | Publication bias | Other considerations | Overall quality |
|--------------------------|---------------|--------------|--------------|-------------|---------------|--------------|------------------|-------------------|-----------------|
| Ferdowsali et al., 2020  | Case report   | Serious      | -            | -           | -             | Not serious  | Serious          | None              | Very low        |
| Carpenter et al., 2019   | Case report   | Serious      | -            | -           | -             | Not serious  | Serious          | None              | Very low        |
| Guo et al., 2019         | Scientific abstract | Serious     | -            | -           | -             | Not serious  | Serious          | None              | Very low        |
| Trilli et al., 1994      | Case report   | Serious      | -            | -           | -             | Not serious  | Serious          | None              | Very low        |
| Quinn et al., 2021       | Scientific abstract | Serious     | -            | -           | -             | Not serious  | Serious          | None              | Very low        |
| Gutierrez et al., 2019   | Scientific abstract | Serious     | -            | -           | -             | Not serious  | Serious          | None              | Very low        |
| Eisenstat et al., 2020   | Scientific abstract | Serious     | -            | -           | -             | Serious      | None              | Very low          |
| Jackson et al., 1993     | Case report   | Serious      | -            | -           | -             | Not serious  | Serious          | None              | Very low        |
| Newby et al., 1995       | Case report   | Serious      | -            | -           | -             | Not serious  | Serious          | None              | Very low        |
| Ulici et al., 2021       | Scientific abstract | Serious     | -            | -           | -             | Not serious  | Serious          | None              | Very low        |
| Wieruszewski et al., 2020| Case report   | Serious      | -            | -           | -             | Not serious  | Serious          | None              | Very low        |
| Tovar et al., 1997       | Case report   | Serious      | -            | -           | -             | Not serious  | Serious          | None              | Very low        |
| Chieng et al., 2021      | Case report   | Serious      | -            | -           | -             | Not serious  | Serious          | None              | Very low        |

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s13181-022-00885-4.

Funding Open Access funding enabled and organized by CAUL and its Member Institutions.

Declarations

Conflicts of Interest None.

Sources of Funding None.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Gamper G, Havel C, Arrich J, Losert H, Pace NL, Mullner M, et al. Vasopressors for hypotensive shock. Cochrane Database Syst Rev. 2016;2:CD003709.
2. Walsh M, Devereaux PJ, Garg AX, Kurz A, Turan A, Rodseth RN, et al. Relationship between intraoperative mean arterial pressure and clinical outcomes after noncardiac surgery: toward an empirical definition of hypotension. Anesthesiology. 2013;119(3):507–15.
3. Vincent JL, De Backer D. Circulatory shock. N Engl J Med. 2013;369(18):1726–34.
4. Lumlertgul N, Ostermann M. Roles of angiotensin II as vasopressor in vasodilatory shock. Future Cardiol. 2020;16(6):569–83.
5. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39(2):165–228.
6. Fyhriquist F, Sajjonmaa O. Renin-angiotensin system revisited. J Intern Med. 2008;264(3):224–36.
7. Kumar R, Thomas CM, Yong QC, Chen W, Baker KM. The intracrine renin-angiotensin system. Clin Sci (Lond). 2012;123(5):273–84.
8. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev. 2006;86(3):747–803.
9. Antonucci E, Gleeson PJ, Annoni F, Agosta S, Orlando S, Taccone FS, et al. Angiotensin II in Refractory Septic Shock. Shock (Augusta, Ga). 2017;47(5):560–6.
10. van Kats JP, de Lannoy LM, Jan Danser AH, van Meegen JR, Verdouw PD, Schalekamp MA. Angiotensin II type 1 (AT1) receptor-mediated accumulation of angiotensin II in tissues and its intracellular half-life in vivo. Hypertension. 1997;30(1 Pt 1):42–9.
11. Giapreza (angiotensin II) [package insert]. La Jolla Pharmaceutical Company, San Diego, CA, USA (2018). https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/20936s0005l.pdf. Accessed 20 Dec 2021.
12. Huang J, Buckley NA, Isoardi KZ, Chiew AL, Ishbiger GK, Cairns R, et al. Angiotensin axis antagonists increase the incidence of haemodynamic instability in dihydropyridine calcium channel blocker poisoning. Clin Toxicol (Phila). 2021;59(6):464–71.
13. Rotella JA, Greene SL, Koutsogiannis Z, Graudins A, Hung Leang Y, Kuan K, et al. Treatment for beta-blocker...
poisoning: a systematic review. Clin Toxicol (Phila). 2020;58(10):943–83.
14. Chawla LS, Busse L, Brasha-Mitchell E, Davison D, Honiq J, Alotaibi Z, et al. Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study. Crit Care. 2014;18(5):534.
15. Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, et al. Angiotensin II for the Treatment of Vasodilatory Shock. N Engl J Med. 2017;377(5):419–30.
16. Khalique SC, Ferguson N. Angiotensin II (Giapreza): a distinct mechanism for the treatment of vasodilatory shock. Cardiol Rev. 2019;27(3):167–9.
17. European Medicines Agency (EMA). Giapreza (angiotensin II). https://www.ema.europa.eu/en/documents/product-information/giapreza-epar-product-information_en.pdf. Accessed 20 Dec 2021.
18. Busse LW, McCurdy MT, Ali O, Hall A, Chen H, Ostermann M. The effect of angiotensin II on blood pressure in patients with circulatory shock: a structured review of the literature. Crit Care. 2017;21(1):324.
19. Wakefield BJ, Busse LW, Khanna AK. Angiotensin II in Vasodilatory Shock. Crit Care Clin. 2019;35(2):229–45.
20. Jadhav AP, Sadaka FG. Angiotensin II in septic shock. Am J Emerg Med. 2019;37(6):1169–74.
21. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–6.
22. Mustafa RA, Santesso N, Brozek J, Akl EA, Walter SD, Norman G, et al. The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses. J Clin Epidemiol. 2013;66(7):736–42 (quiz 42 e1–5).
23. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401–6.
24. Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al. GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol. 2011;64(12):1311–6.
25. Newby DE, Lee MR, Gray AJ, Boon NA. Enalapril overdose and the corrective effect of intravenous angiotensin II [1]. Br J Clin Pharmacol. 1995;40(1):103–4.
26. Jackson T, Conk C, Agar J. Enalapril overdose treated with angiotensin infusion. Lancet. 1993;341(8846):703.
27. Ferdowsali J, Ferdowsali K. A patient with tricyclic antidepressant overdose with catecholamine-resistant hypotension rescued with angiotensin II: a case report. Dimensions of critical care nursing. 2015;48(3):249–60.
28. Carpenter JE, Murray BP, Sagahi R, Thomas B, Lee S, Kleinman R, et al. Successful Treatment of Antihypertensive Overdose Using Intravenous Angiotensin II. J Emerg Med. 2019;57(3):339–44.
29. Guo Y, Dotherow P, Wiley T, Wilhelm A. A case of intravenous angiotensin II in the treatment of vasodilatory shock due to drug overdose. Critical Care Medicine. 2019;47(1 Supplement 1).
30. Trilli LE, Johnson KA. Lisinopril overdose and management with intravenous angiotensin II. Ann Pharmacother. 1994;28(10):1165–8.
31. Quinn C, Moukhachen H, Bagnola A, Bank R, Carlson T, Djurkovic S, et al. Successful use of angiotensin ii in a case of refractory vasodilatory cardiogenic mixed shock. Crit Care Med. 2021;49(1 SUPPL 1):646.
32. Gutierrez G, Dayton C, Smedley L, Saikumar H, Everett C, Rodriguez A, et al. Shall we try angiotensin II (Too)? Treatment of refractory shock due to co-ingestion of amiodarone and benazepril: a case report. J Med Toxicol. 2019;15(2):62.
33. Eisenstat MD, Schaak L, Yeh M, Therriault C, Steck A. Death from presumed tamsulosin toxicity. J Med Toxicol. 2020;16(2):127.
34. Ulici A, Oakland CL, Sweat CN, Cole JB. Successful treatment of vasopressor and high-dose insulin resistant shock from polydrug cardiotoxic overdose with methylene blue, angiotensin II, and ECMO. J Med Toxicol. 2021;17:129.
35. Wierszewski PM, Nelson S, Wittwer ED, Leung JG. Vasopressor-Refractory Shock From Clozapine Overdose Treated With Synthetic Angiotensin II Infusion. Crit Care Explor. 2020;2(9):e0185.
36. Tolar JW, Bujons I, Ruiz JC, Ibanez L, Salgado A. Treatment of severe combined overdose of calcium antagonists and converting enzyme inhibitors with angiotensin II. Nephron. 1997;77(2):239.
37. Chien S, Malouf S, Costa-Pinto R, Bellomo R, Géronstamoulos D, Wong A. Severe hand sanitiser (isopropanol) toxicity managed with continuous venovenous haemodiafiltration and angiotensin II. Clin Toxicol (Phila). 2021;59(12):1277–8.
38. Martin C, Medam S, Antonini F, Alingrin J, Haddam M, Hamad E, et al. Norepinephrine: not too much, too long. Shock. 2015;44(4):305–9.
39. Jentzer JC, Vallabha-Josyula S, Khanna AK, Chawla LS, Busse LW, Kashani KB. Management of Refractory Vasodilatory Shock. Chest. 2018;154(2):416–26.
40. Mayr VD, Dunser MW, Greil V, Jochberger S, Luckner G, Ulmer H, et al. Causes of death and determinants of outcome in critically ill patients. Crit Care. 2006;10(6):R154.
41. Jentzer JC, Coons JC, Link CB, Schmidhofer M. Pharmacotherapy update on the use of vasopressors and inotropes in the intensive care unit. J Cardiovasc Pharmacol Ther. 2015;20(3):249–60.
42. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707–10.
43. Dunser MW, Ruokonen E, Pettilia V, Ulmer H, Torgersen C, Schmittinger CA, et al. Association of arterial blood pressure and vasopressor load with septic shock mortality: a post hoc analysis of a multicenter trial. Crit Care. 2009;13(6):R181.
44. Haughey R, Vernick W, Gutsche J, Laudanski K. Use of venovenous extracorporeal membrane oxygenation to treat severe combined calcium channel blocker and angiotensin converting enzyme inhibitor overdose. Perfusion. 2019;34(2):167–9.
45. Murphy L, Rasmussen J, Murphy NG. Venlafaxine overdose treated with extracorporeal life support. CMAJ. 2021;193(5):E167–70.
46. Vignesch C, Kumar M, Venkataraman R, Rajagopal S, Ramakrishnan N, Abraham BK. Extracorporeal membrane oxygenation in drug overdose: a clinical case series. Indian J Crit Care Med. 2018;22(2):111–5.
47. Napp LC, Kuhn C, Bauersachs J. ECMO in cardiac arrest and cardiogenic shock. Herz. 2017;42(1):27–44.
48. Ostermann M, Boldt DW, Harper MD, Lim GW, Gunnerson K. Angiotensin in ECMO patients with refractory shock. Crit Care. 2018;22(1):288.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.